AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Solute carrier family 12 member 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UHW9

UPID:

S12A6_HUMAN

Alternative names:

Electroneutral potassium-chloride cotransporter 3; K-Cl cotransporter 3

Alternative UPACC:

Q9UHW9; A0AV76; Q2VI00; Q7Z2E7; Q7Z4G5; Q8TDD4; Q9UFR2; Q9Y642; Q9Y665

Background:

Solute carrier family 12 member 6, also known as the electroneutral potassium-chloride cotransporter 3 (K-Cl cotransporter 3), plays a crucial role in maintaining cell volume homeostasis. It mediates potassium-chloride cotransport in response to cell swelling, a process vital for the normal functioning of cells.

Therapeutic significance:

The protein is implicated in severe diseases such as Agenesis of the corpus callosum, with peripheral neuropathy, and Charcot-Marie-Tooth disease, axonal, 2II. These conditions highlight the protein's critical role in nerve function and development, suggesting that targeting this cotransporter could offer new avenues for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.